CPSI, PROT, PMC - 21st Century Healthcare & Technologies Stock, Update!
Sunday, September 5th, 2010
________
Proteonomix, Inc. (PROT) Plans European Investor Road Show
-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors
PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced last week that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.
For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.
“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).
________
Computer Programs and Systems, Inc. (NASDAQ:CPSI)
CPSI, a leading provider of healthcare information solutions, recently announced results for the second quarter and six months ended June 30, 2010.
The Company also announced that its Board of Directors has declared a regular quarterly cash dividend of $0.36 (thirty-six cents) per share, payable on August 27, 2010, to stockholders of record as of the close of business on August 12, 2010.
Total revenues for the second quarter ended June 30, 2010, increased 22.3% to $37.7 million, compared with total revenues of $30.8 million for the prior-year period. Net income for the quarter ended June 30, 2010, increased 20.4% to $4.3 million, or $0.39 per diluted share, compared with $3.5 million, or $0.32 per diluted share, for the quarter ended June 30, 2009. Cash provided by operations for the second quarter of 2010 was $2.8 million, compared with $3.7 million of cash provided by operations for the prior-year period.
________
PharMerica Corporation Announces Share Repurchase Program
PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, recently announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company’s common stock. The share repurchases will be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash.
The amount and timing of the repurchases will be determined by the Company’s management and will depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program will be held as treasury shares and may be used for general corporate purposes, including reissuances in connection with acquisitions, employee stock option exercises or other employee stock plans.
The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice.
PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. As of June 30, 2010, PharMerica operated 90 institutional pharmacies in 41 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.
________
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).
